Laboratory Testing for von Willebrand Disease: The Past, Present, and Future State of Play for von Willebrand Factor Assays that Measure Platelet Binding Activity, with or without Ristocetin

Abstract

von Willebrand disease (VWD) was first described nearly a century ago in 1924 by Erik Adolf von Willebrand. Diagnostic testing at the time was very limited and it was not until the mid to late 1900s that more tests became available to assist with the diagnosis and classification of VWD. Two of these tests are based on ristocetin, one being ristocetin-induced platelet aggregation (RIPA) and the other the von Willebrand factor (VWF) ristocetin cofactor assay (VWF:RCo). The VWF:RCo assay provides functional assessment of in vitro VWF binding to the platelet glycoprotein (Gp) complex, GPIb-IX-V. Despite some advancements and newer technologies utilizing the principles of the original VWF:RCo assay, the original assay is still referred to as the gold standard for measurement of VWF activity. This article will review the history of VWD diagnostic assays, including RIPA and VWF:RCo over the past 40 years, as well as the newer assays that measure platelet binding with or without ristocetin, and which have been developed with the aim to potentially replace platelet-based ristocetin-dependent assays.

Keywords

ristocetin cofactor - ristocetin induced platelet aggregation - von Willebrand disease - laboratory testing - von Willebrand factor - von Willebrand factor activity

• References

• 1 Favaloro EJ. Laboratory identification of von Willebrand disease: technical and scientific perspectives. Semin Thromb Hemost 2006; 32 (5) 456-471
• 2 Sadler JE, Budde U, Eikenboom JC , et al; Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4 (10) 2103-2114
• 3 Lassila R, Lindberg O. Erik von Willebrand. Haemophilia 2013; 19 (5) 643-647
• 4 Duke WW. The pathogenesis of purpure hemorrhagica with special reference to the part played by blood platelets. Arch Intern Med 1912; 10: 445-469
• 5 Ivy AC, Nelson D, Bucher G. The standardization of certain factors in the cutaneous “venostasis bleeding time technique”. J Lab Clin Med 1941; 26 (11) 1812-1822
• 6 Borchgrevink CF. Platelet adhesion in vitro in patients with bleeding disorders. Acta Med Scand 1961; 170 (2) 231-243
• 7 Salzman EW. Measurement of platelet adhesiveness: a simple in vitro technique demonstrating abnormality in von Willebrand's disease. J Lab Clin Med 1963; 62: 724-735
• 8 Bowie EJM, Owen Jr CA, Thompson Jr JH, Didisheim P. Platelet adhesiveness in von Willebrand's disease. Am J Clin Pathol 1969; 52 (1) 69-77
• 9 Rodgers RP, Levin J. A critical reappraisal of the bleeding time. Semin Thromb Hemost 1990; 16 (1) 1-20
• 10 Lind SE. The bleeding time does not predict surgical bleeding. Blood 1991; 77 (12) 2547-2552
• 11 Howard MA, Firkin BG. Ristocetin—a new tool in the investigation of platelet aggregation. Thromb Diath Haemorrh 1971; 26 (2) 362-369
• 12 Howard MA, Sawers RJ, Firkin BG. Ristocetin: a means of differentiating von Willebrand's disease into two groups. Blood 1973; 41 (5) 687-690
• 13 Weiss HJ, Hoyer LW, Rickles FR, Varma A, Rogers J. Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content. J Clin Invest 1973; 52 (11) 2708-2716
• 14 Jenkins CS, Meyer D, Dreyfus MD, Larrieu MJ. Willebrand factor and ristocetin. I. Mechanism of rustocetin-induced platelet aggregation. Br J Haematol 1974; 28 (4) 561-578
• 15 Olson JD, Brockway WJ, Fass DN, Magnuson MA, Bowie EJ. Evaluation of ristocetin-Willebrand factor assay and ristocetin-induced platelet aggregation. Am J Clin Pathol 1975; 63 (2) 210-218
• 16 Ruggeri ZM, Pareti FI, Mannucci PM, Ciavarella N, Zimmerman TS. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease. N Engl J Med 1980; 302 (19) 1047-1051
• 17 Takahashi H. Studies on the pathophysiology and treatment of von Willebrand's disease. IV. Mechanism of increased ristocetin-induced platelet aggregation in von Willebrand's disease. Thromb Res 1980; 19 (6) 857-867
• 18 Miller JL, Castella A. Platelet-type von Willebrand's disease: characterization of a new bleeding disorder. Blood 1982; 60 (3) 790-794
• 19 Weiss HJ, Meyer D, Rabinowitz R , et al. Pseudo-von Willebrand's disease. An intrinsic platelet defect with aggregation by unmodified human factor VIII/von Willebrand factor and enhanced adsorption of its high-molecular-weight multimers. N Engl J Med 1982; 306 (6) 326-333
• 20 Phillips DR, Jennings LK, Edwards HH. Identification of membrane proteins mediating the interaction of human platelets. J Cell Biol 1980; 86 (1) 77-86
• 21 Coller BS, Peerschke EI, Scudder LE, Sullivan CA. Studies with a murine monoclonal antibody that abolishes ristocetin-induced binding of von Willebrand factor to platelets: additional evidence in support of GPIb as a platelet receptor for von Willebrand factor. Blood 1983; 61 (1) 99-110
• 22 Sadler JE ; For the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. A revised classification of von Willebrand disease. Thromb Haemost 1994; 71 (4) 520-525
• 23 Miller CH, Platt SJ, Daniele C, Kaczor D. Evaluation of two automated methods for measurement of the ristocetin cofactor activity of von Willebrand factor. Thromb Haemost 2002; 88 (1) 56-59
• 24 Lattuada A, Preda L, Sacchi E, Gallo L, Federici AB, Rossi E. A rapid assay for ristocetin cofactor activity using an automated coagulometer (ACL 9000). Blood Coagul Fibrinolysis 2004; 15 (6) 505-511
• 25 Redaelli R, Corno AR, Borroni L , et al. von Willebrand factor ristocetin cofactor (VWF:RCo) assay: implementation on an automated coagulometer (ACL). J Thromb Haemost 2005; 3 (12) 2684-2688
• 26 Strandberg K, Lethagen S, Andersson K, Carlson M, Hillarp A. Evaluation of a rapid automated assay for analysis of von Willebrand ristocetin cofactor activity. Clin Appl Thromb Hemost 2006; 12 (1) 61-67
• 27 Bowyer AE, Shepherd F, Kitchen S, Makris M. A rapid, automated VWF ristocetin cofactor activity assay improves reliability in the diagnosis of Von Willebrand disease. Thromb Res 2011; 127 (4) 341-344
• 28 Lawrie AS, Mackie IJ, Machin SJ, Peyvandi F. Evaluation of an automated platelet-based assay of ristocetin cofactor activity. Haemophilia 2011; 17 (2) 252-256
• 29 Hillarp A, Stadler M, Haderer C, Weinberger J, Kessler CM, Römisch J. Improved performance characteristics of the von Willebrand factor ristocetin cofactor activity assay using a novel automated assay protocol. J Thromb Haemost 2010; 8 (10) 2216-2223
• 30 Favaloro EJ, Mohammed S, McDonald J. Validation of improved performance characteristics for the automated von Willebrand factor ristocetin cofactor activity assay. J Thromb Haemost 2010; 8 (12) 2842-2844
• 31 Favaloro EJ, Mohammed S. Towards improved diagnosis of von Willebrand disease: comparative evaluations of several automated von Willebrand factor antigen and activity assays. Thromb Res 2014; 134 (6) 1292-1300
• 32 Vanhoorelbeke K, Cauwenberghs N, Vauterin S, Schlammadinger A, Mazurier C, Deckmyn H. A reliable and reproducible ELISA method to measure ristocetin cofactor activity of von Willebrand factor. Thromb Haemost 2000; 83 (1) 107-113
• 33 Federici AB, Canciani MT, Forza I , et al. A sensitive ristocetin co-factor activity assay with recombinant glycoprotein Ibalpha for the diagnosis of patients with low von Willebrand factor levels. Haematologica 2004; 89 (1) 77-85
• 34 Murdock PJ, Woodhams BJ, Matthews KB, Pasi KJ, Goodall AH. von Willebrand factor activity detected in a monoclonal antibody-based ELISA: an alternative to the ristocetin cofactor platelet agglutination assay for diagnostic use. Thromb Haemost 1997; 78 (4) 1272-1277
• 35 Flood VH, Gill JC, Morateck PA , et al. Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD. Blood 2011; 117 (6) e67-e74
• 36 Lindahl TL, Fagerberg IH, Larsson A. A new flow cytometric method for measurement of von Willebrand factor activity. Scand J Clin Lab Invest 2003; 63 (3) 217-223
• 37 Giannini S, Mezzasoma AM, Leone M, Gresele P. Laboratory diagnosis and monitoring of desmopressin treatment of von Willebrand's disease by flow cytometry. Haematologica 2007; 92 (12) 1647-1654
• 38 Chen D, Daigh CA, Hendricksen JI , et al. A highly-sensitive plasma von Willebrand factor ristocetin cofactor (VWF:RCo) activity assay by flow cytometry. J Thromb Haemost 2008; 6 (2) 323-330
• 39 Pinol M, Costa M, Sales M, Federici AB, Canciani MT. New automated von Willebrand factor activity assay to distinguish type I and type 2 von Willebrand disease. J Thromb Hemost 2003; Suppl S1: P1679
• 40 Piñol M, Sales M, Costa M, Tosetto A, Canciani MT, Federici AB. Evaluation of a new turbidimetric assay for von Willebrand factor activity useful in the general screening of von Willebrand disease. Haematologica 2007; 92 (5) 712-713
• 41 De Vleeschauwer A, Devreese K. Comparison of a new automated von Willebrand factor activity assay with an aggregation von Willebrand ristocetin cofactor activity assay for the diagnosis of von Willebrand disease. Blood Coagul Fibrinolysis 2006; 17 (5) 353-358
• 42 Sucker C, Senft B, Scharf RE, Zotz RB. Determination of von Willebrand factor activity: evaluation of the HaemosIL assay in comparison with established procedures. Clin Appl Thromb Hemost 2006; 12 (3) 305-310
• 43 Salem RO, Van Cott EM. A new automated screening assay for the diagnosis of von Willebrand disease. Am J Clin Pathol 2007; 127 (5) 730-735
• 44 Trossaërt M, Ternisien C, Lefrancois A , et al. Evaluation of an automated von Willebrand factor activity assay in von Willebrand disease. Clin Appl Thromb Hemost 2011; 17 (6) E25-E29
• 45 Chen D, Tange JI, Meyers BJ, Pruthi RK, Nichols WL, Heit JA. Validation of an automated latex particle-enhanced immunoturbidimetric von Willebrand factor activity assay. J Thromb Haemost 2011; 9 (10) 1993-2002
• 46 Lasne D, Dey C, Dautzenberg MD , et al. Screening for von Willebrand disease: contribution of an automated assay for von Willebrand factor activity. Haemophilia 2012; 18 (3) e158-e163
• 47 Pinol M, Sanchez T, Sales M, Arnout J, van Russelt M. New automated ristocetin cofactor activity assay to distinguish type I and type 2 von Willebrand disease (VWD). J Thromb Haemost 2009;
• 48 Stufano F, Lawrie AS, La Marca S, Berbenni C, Baronciani L, Peyvandi F. A two-centre comparative evaluation of new automated assays for von Willebrand factor ristocetin cofactor activity and antigen. Haemophilia 2014; 20 (1) 147-153
• 49 Lawrie AS, Stufano F, Canciani MT, Mackie IJ, Machin SJ, Peyvandi F. A comparative evaluation of a new automated assay for von Willebrand factor activity. Haemophilia 2013; 19 (2) 338-342
• 50 Geisen U, Zieger B, Nakamura L , et al. Comparison of Von Willebrand factor (VWF) activity VWF:Ac with VWF ristocetin cofactor activity VWF:RCo. Thromb Res 2014; 134 (2) 246-250
• 51 Reilly-Stitt C, Coppell J, Mumford AD. Discrepancy in von Willebrand factor activity determined by ristocetin cofactor and immunotubidometric assays. Haemophilia 2014; 20 (4) e341-e344
• 52 Graf L, Moffat KA, Carlino SA , et al. Evaluation of an automated method for measuring von Willebrand factor activity in clinical samples without ristocetin. Int J Lab Hematol 2014; 36 (3) 341-351
• 53 Patzke J, Budde U, Huber A , et al. Performance evaluation and multicentre study of a von Willebrand factor activity assay based on GPIb binding in the absence of ristocetin. Blood Coagul Fibrinolysis 2014; 25 (8) 860-870
• 54 Timm A, Hillarp A, Philips M, Goetze JP. Comparison of automated von Willebrand factor activity assays. Thromb Res 2015; 135 (4) 684-691
• 55 Verfaillie CJ, De Witte E, Devreese KMJ. Validation of a new panel of automated chemiluminescence assays for von Willebrand factor antigen and activity in the screening for von Willebrand disease. Int J Lab Hematol 2013; 35 (5) 555-565
• 56 Cabrera N, Moret A, Caunedo P , et al. Comparison of a new chemiluminescent immunoassay for von Willebrand factor activity with the ristocetin cofactor-induced platelet agglutination method. Haemophilia 2013; 19 (6) 920-925
• 57 de Maistre E, Volot F, Mourey G , et al. Performance of two new automated assays for measuring von Willebrand activity: HemosIL AcuStar and Innovance. Thromb Haemost 2014; 112 (4) 825-830
• 58 Costa-Pinto J, Pérez-Rodríguez A, del C Goméz-del-Castillo M , et al. Diagnosis of inherited von Willebrand disease: comparison of two methodologies and analysis of the discrepancies. Haemophilia 2014; 20 (4) 559-567
• 59 Favaloro EJ, Mohammed S. Evaluation of a von Willebrand factor three test panel and chemiluminescent-based assay system for identification of, and therapy monitoring in, von Willebrand disease. Thromb Res 2016; 141: 202-211
• 60 Sagheer S, Rodgers S, Yacoub O, Dauer R, Mcrae S, Duncan E. Comparison of von Willebrand factor (VWF) activity levels determined by HemosIL AcuStar assay and HemosIL LIA assay with ristocetin cofactor assay by aggregometry. Haemophilia 2016; 22 (3) e200-e207
• 61 Bodo J, Eikenboom J, Montgomery R, Patzke J, Schneppenheim R, Di Paola J ; von Willebrand factor Subcommittee of the Standardization and Scientific Committee of the International Society for Thrombosis and Haemostasis. Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH. J Thromb Haemost 2015; 13 (7) 1345-1350
• 62 Born GVR. Quantitative investigation into the aggregation of blood platelets. J Physiol 1962; 162: 67-68
• 63 Grundy WE, Sinclair AC, Theriault RJ , et al. Ristocetin, microbiologic properties. Antibiot Annu 1956– 1957; 687-692
• 64 Gangarosa EJ, Landerman NS, Rosch PJ, Herndon Jr EG. Hematologic complications arising during ristocetin therapy; relation between dose and toxicity. N Engl J Med 1958; 259: 156-161
• 65 Van der Weyden MB, Clancy RL, Howard MA, Firkin BG. Qualitative platelet defects with reduced life-span in acute leukaemia. Aust N Z J Med 1972; 2 (4) 339-345
• 66 Clancy R, Jenkins E, Firkin B. Qualitative platelet abnormalities in idiopathic thrombocytopenic purpura. N Engl J Med 1972; 286 (12) 622-626
• 67 Clancy R, Jenkins E, Firkin B. Platelet defect of infectious mononucleosis. BMJ 1971; 4 (5788) 646-648
• 68 Howard MA, Hutton RA, Hardisty RM. Hereditary giant platelet syndrome: a disorder of a new aspect of platelet function. BMJ 1973; 2 (5866) 586-588
• 69 Laffan MA, Lester W, O'Donnell JS , et al. The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology. Br J Haematol 2014; 167 (4) 453-465
• 70 Nichols WL, Hultin MB, James AH , et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008; 14 (2) 171-232
• 71 Allain JP, Cooper HA, Wagner RH, Brinkhous KM. Platelets fixed with paraformaldehyde: a new reagent for assay of von Willebrand factor and platelet aggregating factor. J Lab Clin Med 1975; 85 (2) 318-328
• 72 Brinkhous KM, Graham JE, Cooper HA, Allain JP, Wagner RH. Assay of von Willebrand factor in von Willebrand's disease and hemophilia: use of a macroscopic platelet aggregation test. Thromb Res 1975; 6 (3) 267-272
• 73 Italian Working Group. Spectrum of von Willebrand's disease: a study of 100 cases. Br J Haematol 1977; 35 (1) 101-112
• 74 Favaloro EJ, Mehrabani PA, Koutts J. Laboratory assessment of von Willebrand factor: altered interpretation of laboratory data, and altered diagnosis of von Willebrand's disease, as influenced by the use of different VWF assays and assay conditions. Clin Appl Thromb Hemost 1997; 3: 110-118
• 75 Favaloro EJ, Koutts J. Laboratory assays for von Willebrand factor: relative contribution to the diagnosis of von Willebrand's disease. Pathology 1997; 29 (4) 385-391
• 76 Favaloro EJ, Smith J, Pettinos P, Hertzberg M, Koutts J. Laboratory testing for von Willebrand disease: An Assessment of Current Diagnostic Practise and Efficacy by Means of a Multi-laboratory Survey. RCPA Quality Assurance Program (QAP) in Haematology Haemostasis Scientific Advisory Panel. Thromb Haemost 1999; 82 (4) 1207-1379
• 77 Favaloro EJ, Thom J, Baker R ; Australasian Society for Thrombosis and Haemostasis (ASTH) Emerging Technologies Group. Assessment of current diagnostic practice and efficacy in testing for von Willebrand's disorder: results from the second Australasian multi-laboratory survey. Blood Coagul Fibrinolysis 2000; 11 (8) 729-737
• 78 Favaloro EJ, Bonar R, Kershaw G , et al; RCPA QAP in Haematology. Laboratory diagnosis of von Willebrand's disorder: quality and diagnostic improvements driven by peer review in a multilaboratory test process. Haemophilia 2004; 10 (3) 232-242
• 79 Favaloro EJ, Bonar R, Marsden K. Lower limit of assay sensitivity: an under-recognised and significant problem in von Willebrand disease identification and classification. Clin Lab Sci 2008; 21 (3) 178-183
• 80 Chandler WL, Peerschke EI, Castellone DD, Meijer P . NASCOLA Proficiency Testing Committee. Von Willebrand factor assay proficiency testing. The North American Specialized Coagulation Laboratory Association experience. Am J Clin Pathol 2011; 135 (6) 862-869
• 81 Kitchen S, Jennings I, Woods TA, Kitchen DP, Walker ID, Preston FE. Laboratory tests for measurement of von Willebrand factor show poor agreement among different centers: results from the United Kingdom National External Quality Assessment Scheme for Blood Coagulation. Semin Thromb Hemost 2006; 32 (5) 492-498
• 82 Hayes TE, Brandt JT, Chandler WL , et al. External peer review quality assurance testing in von Willebrand disease: the recent experience of the United States College of American Pathologists proficiency testing program. Semin Thromb Hemost 2006; 32 (5) 499-504
• 83 Meijer P, Haverkate F. An external quality assessment program for von Willebrand factor laboratory analysis: an overview from the European concerted action on thrombosis and disabilities foundation. Semin Thromb Hemost 2006; 32 (5) 485-493
• 84 Favaloro EJ, Bonar R, Sioufi J , et al; RCPA Quality Assurance Program in Haematology Haemostasis Committee. Laboratory diagnosis of von Willebrand disorder. Current practice in the southern hemisphere. Am J Clin Pathol 2003; 119 (6) 882-893
• 85 Kricka LJ. Human anti-animal antibody interferences in immunological assays. Clin Chem 1999; 45 (7) 942-956
• 86 Gardiner C, Pennaneac'h C, Mackie IJ, Sheldrake A, Harrison J, Machin SJ. Falsely elevated D-dimer results in a healthy patient on account of heterophiletul antibodies. Br J Haematol 2003; 122 (5) 871-873
• 87 Flood VH, Friedman KD, Gill JC , et al. No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation. Blood 2013; 121 (18) 3742-3744
• 88 Flood VH, Gill JC, Morateck PA , et al. Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor. Blood 2010; 116 (2) 280-286
• 89 Russell SD, Roth GJ. Pseudo-von Willebrand disease: a mutation in the platelet glycoprotein Ib alpha gene associated with a hyperactive surface receptor. Blood 1993; 81 (7) 1787-1791
• 90 Favaloro EJ, Thom J, Patterson D , et al. Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays?. Thromb Res 2009; 123 (6) 862-868
• 91 Favaloro EJ, Bonar RA, Meiring M , et al. Evaluating errors in the laboratory identification of von Willebrand disease in the real world. Thromb Res 2014; 134 (2) 393-403
• 92 Mazurier C, Rodeghiero F . von Willebrand Factor Subcommittee of the Scientific Standardization Committee of the International Society of Thrombosis and Haemostasis. Recommended abbreviations for von Willebrand Factor and its activities. J Thromb Haemost 2001; 86 (2) 712
• 93 Lippi G, Plebani M, Favaloro EJ. The changing face of hemostasis testing in modern laboratories: consolidation, automation, and beyond. Semin Thromb Hemost 2015; 41 (3) 294-299